NCT00297362View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

CompletedOBSERVATIONAL

Enrollment

344

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

October 31, 2005

Conditions

Alzheimer Disease

Interventions

DRUG

Galantamine hydrobromide

247 patients with diagnosed mild to moderate Alzheimer disease.

All Listed Sponsors

lead

Janssen Cilag Pharmaceutica S.A.C.I., Greece

INDUSTRY

NCT00297362 - A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter